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Background: Acute respiratory distress syndrome (ARDS) is characterized by the development of
noncardiogenic pulmonary edema, which has been related to the bioactivity of vascular endothelial growth
factor (VEGF). Vascular endothelial growth factor receptors and coreceptors regulate this bioactivity. We
hypothesized VEGF receptors 1 and 2 (VEGFR1, VEGFR2) and coreceptor neuropilin-1 (NRP-1) would
be expressed in human lung tissue with a significant change in expression in ARDS lung.
Methods: Archival “normal” (no lung pathology and non-ARDS), “early” (within 48 hours), and “later”
(after day 7) ARDS lung-tissue sections (n = 5) were immunostained for VEGFR1, VEGFR2, and NRP-1
from human subjects (n = 4). Staining was assessed densitometrically using Histometrix software.
Results: VEGFR1, VEGFR2, and NRP-1 were expressed on both sides of the alveolar-capillary
membrane in both normal and ARDS human lung tissue. In later ARDS, there was a significant up-
regulation of VEGFR1 andVEGFR2 versus normal and early ARDS (P b .0001). Neuropilin-1 was down-
regulated in early ARDS versus normal lung (P b .05), with normalization in later ARDS (P b .001).
Conclusion: Differential temporal VEGFR1, VEGFR2, and NRP-1 up-regulation occurs in human ARDS,
providing evidence of further functional regulation ofVEGFbioactivity viaVEGFR2consistentwith aprotective
role for VEGF in lung injury recovery. The mechanisms behind these observations remain to be clarified.
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oi:10.1016/j.jcrc.2008.04.003Acute respiratory distress syndrome (ARDS) is the most
extreme form of acute lung injury. It is characterized by
noncardiogenic pulmonary edema, neutrophilic alveolitis,
and the development of potentially reversible fibrosis, but its
pathogenesis still remains incompletely explained [1].
Vascular endothelial growth factor (VEGF) is a potent
angiogenic factor of critical importance in vascular devel-
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and mitogenic factor on vascular endothelium have led to
investigating its possible role in ARDS [3-6], which
continues to have an unacceptable morbidity and mortality
of at least 35% despite improvements in management of
sepsis and ventilatory support [7].
Observational data show plasma soluble VEGF levels rise
and intrapulmonary levels fall in the early stages of lung
injury with normalization of both during recovery [3,4,8].
Vascular endothelial growth factor protein is compartmenta-
lized to high levels in normal human epithelial lining fluid,
and human type 2 epithelial (ATII) cells express significant
amounts of VEGF protein in vitro [9,10].
Vascular endothelial growth factor exerts its biological
effect on vascular endothelium through specific receptors,
VEGFR1 and VEGFR2. They have 7 immunoglobulin-like
domains with specific functions, a single transmembrane
region, and a consensus tyrosine kinase sequence interrupted
by a kinase-insert domain [11]. Vascular endothelial growth
factor also acts indirectly via the coreceptor neuropilin-1
(NRP-1), which augments VEGFR2 signaling activity but
lacks tyrosine kinase activity itself and is therefore only able
to act indirectly via effects on VEGFR2 activity [12,13].
Vascular endothelial growth factor receptor 2 is thought to
be the main signaling receptor [14], and VEGFR1 has been
speculated to function as a decoy receptor [15]. Both of these
receptors were initially thought to be largely confined to the
vascular bed (on endothelial cells), but studies in animal and
developing human lung confirm expression in lung tissue
on activated macrophages and respiratory epithelial cells
[16-18]. This implies that VEGF can exert its biological
effects in the alveolar compartment as well as the vascular
bed and is the subject of ongoing study.
As well as functionally regulating VEGF bioactivity,
VEGF receptors are themselves subject to functional
regulation by oxygen tension and VEGF itself, at least in
the vascular bed. Chronic hypoxia up-regulates VEGFR1 and
VEGFR2 expression in vivo [19]. Vascular endothelial
growth factor receptor 1 has a hypoxia-inducible factor 1
consensus sequence in its promoter region, whereas VEGFR2
does not and is thought to be up-regulated by posttranscrip-
tional paracrine mechanisms [20]. Vascular endothelial
growth factor activation of VEGFR2 increases VEGFR2
gene expression and cellular levels, and VEGF can also up-
regulate VEGFR1 expression in endothelial cells [21,22].
One explanation for the observed reduction in soluble
intrapulmonary VEGF levels in early ARDS would be an
increased expression of VEGF receptors facilitating an
increased number of VEGF binding sites. Other possibilities
(which are not mutually exclusive) include an alteration in
alternate splicing or soluble VEGF inhibitors which have
been investigated elsewhere [23]. We therefore hypothesized
that VEGFR1, VEGFR2, and NRP-1 would be expressed in
the adult human lung alveolar compartment as well as the
vascular bed with dynamic temporal changes in expression in
ARDS consistent with a role in lung repair after injury.2. Methods
2.1. Specimens
Archival normal and ARDS lung-tissue sections and
paraffin blocks were obtained from Frenchay Pathology
Department. The North Bristol NHS Trust Local Research
Ethics Committee approved this study.
2.2. Immunohistochemistry
Normal, early, and late ARDS lung-tissue sections were
obtained from human subjects (n = 4 for each group).
Normal lung tissue implied that there was no lung
involvement in the cause of death and no ARDS. Acute
respiratory distress syndrome lung tissue was subdivided
into “early” (within 48 hours of onset) and “late” (after
day 7). Paraffinized 4-μm sections (n = 5 for each subject)
were dewaxed in serial xylene (BDH Laboratory Supplies,
Poole, UK), dehydrated in absolute ethanol (BDH Limited
Laboratory Supplies), and pressure cooked in 0.01 M
trisodium citrate (BDH Laboratory Supplies) buffer (pH 6)
to facilitate antigen retrieval. Saponin (0.1%; Sigma-
Aldrich, Dorset, UK) in phosphate-buffered saline (Oxoid,
Basingstoke, UK), pH 7.3, was used as a wash buffer and
antibody diluent. Endogenous peroxidase was blocked with
3% hydrogen peroxide (BDH Laboratory Supplies) in
methanol (BDH Laboratory Supplies).
Sections were incubated in 2.5% horse blocking serum
(Vectastain Universal Quick Kit; Vector Laboratories,
Peterborough, UK) before avidin D and biotin blocking
sera (Vector Laboratories). Rabbit polyclonal antibodies to
VEGFR1, VEGFR2, and NRP-1 (Autogen Bioclear; UK
Ltd, Wiltshire, UK) were used as primary antibodies.
Isotypic rabbit immunoglobulin G (Vector Laboratories) at
the same concentration was used as a negative control. A
pan-specific biotinylated antibody, streptavidin-peroxidase
complex with diaminobenzidine substrate (Vectastain Uni-
versal Quick Kit; Vector Laboratories) was added. Sections
were counterstained in hematoxylin (BDH Laboratory
Supplies) before serial washes in absolute ethanol and
xylene before mounting with Distrene-80 Plasticizer Xylene
(DPX) (BDH Laboratory Supplies). Image capture and
quantitative densitometry were performed with Histometrix
software (Kinetic Imaging Limited,Wirral, Merseyside, UK).
2.3. Statistical analysis
All statistical analyses were performed using Graph-
Pad Prism version 4.0 software. Data in bar charts are
plotted as mean and standard error. Quantitative immu-
nostaining Histometrix pixel staining densities were
normally distributed as assessed by the Ryan-Joiner
test. Because of the necessity for multiple comparisons
of the data, analysis of variance testing was followed by
Fig. 1 Isotypic control staining in early ARDS lung (original
magnification, ×40).
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considered significant.
3. Results
3.1. Immunohistochemistry
Indirect immunohistochemistry revealed no evidence
of nonspecific staining using isotypic negative control anti-Fig. 2 A–C, VEGFR2 (A), NRP-1 (B), and VEGFR1 (C) expression in
endothelium strong. Expression of all receptors noted on alveolar epitheliu
to be higher generally in normal lung. AM indicates alveolar macrophagbodies confirming that positive staining was significant
(Fig. 1). In addition to expected vascular endothelial expres-
sion, VEGFR1, VEGFR2, and NRP-1 expression was noted
on alveolar epithelium and macrophages (Figs. 2–4A–C).
On direct visualization (before densitometry), differential
immunostaining was noted. In normal lung tissue, VEGFR2
staining was most intense (Fig. 2A). In early ARDS, a relative
loss of alveolar epithelial expression of VEGFR1, VEGFR2,
and NRP-1 especially the latter was noted (Fig. 3A–C). In
later ARDS, there was marked up-regulation of expression of
VEGFR1, VEGFR2, and NRP-1, although of less magnitude
with the latter (Fig. 4A–C).
3.2. Staining densitometry
Histometrix densitometric analysis supported the visual
observations noticed in immunostaining and is presented
graphically in Fig. 5A–C. Differential time-dependent
changes in VEGFR1, VEGFR2, and NRP-1 expression
were noted. Vascular endothelial growth factor receptors 1
and 2 expression was significantly up-regulated in the later
stages of ARDS (P b .001, Bonferroni) versus normal and
early ARDS lung (Fig. 5A–B).
In contrast to VEGFR1 and VEGFR2, NRP-1 expres-
sion was down-regulated in early ARDS lung (P b .05, Bon-
ferroni) versus normal lung with significant up-regulation
in later ARDS (P b .001, Bonferroni) versus early ARDS
(Fig. 5C). Moreover, unlike the other receptors, later ARDSnormal lung (original magnification, ×40). Receptor expression on
m and macrophages. Relative VEGFR2 expression generally noted
es; AE, alveolar epithelium; VE, vascular endothelium.
Fig. 3 A–C, VEGFR2 (A), NRP-1 (B), and VEGFR1 (C) expression in early ARDS showing consistently reduced alveolar expression of
VEGFR2 and NRP-1 (highlighted; original magnification, ×40). Endothelial and macrophage expression as before. AM indicates alveolar
macrophages; AE, alveolar epithelium; VE: vascular endothelium.
Fig. 4 A–C, VEGFR2 (A), NRP-1 (B), and VEGFR1 (C) expression in later ARDS lung (original magnification, ×40). Increased expression
for all receptors noted on alveolar epithelium, macrophages, and endothelium. AM indicates alveolar macrophages; AE, alveolar epithelium;
VE, vascular endothelium.
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Fig. 5 A–C, Graphs of quantitative immunostaining densities
(plotted as pixels of staining per unit area) for VEGFR1 (A),
VEGFR2 (B), and NRP-1 (C) in each disease state. All data are
normally distributed and plotted as mean and standard error. A–B,
P b .001 (Bonferroni) for normal versus late and early versus late
(highlighted*); otherwise, other comparisons are not significant. C,
P b .001 (Bonferroni) for early versus late (highlighted*); P b .05
(Bonferroni) for normal versus early (highlighted†); otherwise,
other comparisons are not significant.
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lung (Fig. 5C).4. Discussion
Vascular endothelial growth factor is compartmentalized
to high levels in normal human epithelial lining fluid, 500
times higher than plasma levels [9]. In health, significant
angiogenesis does not occur in the lung, implying that this
VEGF reservoir has another function. Observational data
suggest that VEGF may have a role in recovery from lung
injury with temporal alterations in plasma and intrapulmon-ary VEGF levels correlating with injury and normalization in
recovery [3,4].
Potential explanations for this apparent reduction in
intrapulmonary VEGF levels in early ARDS are manifold
and not mutually exclusive. Vascular endothelial growth
factor bioactivity is subject to functional regulation including
by VEGF receptors and coreceptors. Vascular endothelial
growth factor receptors are themselves subject to functional
regulation by oxygen tension andVEGF itself. One important
explanation for the VEGF reduction in early ARDS is by up-
regulated specific VEGF receptor expression.
We therefore assessed VEGF-specific receptor (VEGFR1,
VEGFR2) and coreceptor NRP-1 expression by immuno-
histochemistry in archival normal and ARDS lung tissue,
anticipating that functional regulation might occur. We found
VEGFR1, VEGFR2, and NRP-1 expression on alveolar
macrophages and epithelium (consistent with data from
animal and developing lung studies) [16-18] in addition to
their known expression on vascular endothelium. We have
demonstrated differential up-regulation of VEGFR1,
VEGFR2, and NRP-1 expression in human ARDS. Neuro-
pilin-1 was uniquely down-regulated in early ARDS with up-
regulation in later ARDS. VEGFR1 and VEGFR2 were up-
regulated in later ARDS. Our data are consistent with a
reduced VEGFR2 (due to reduced NRP-1) in early ARDS
with an up-regulated VEGFR2 signal (via up-regulation of
VEGFR2 and NRP-1) in later ARDS.
As VEGFR2 is the main VEGF signaling receptor, these
data are consistent with a role of VEGF in repair after lung
injury. We speculate that the up-regulation of decoy receptor
VEGFR1 in later ARDS may serve as a functional and
spatial regulator of VEGF activity via VEGFR2. Although
statistical comparison between the different receptor staining
was not possible (as different antibody affinities would not
have been identical), the staining intensities of both
VEGFR2 (7450 pixels/unit area) and NRP-1 (5920 pixels/
unit area) were noted to be higher than for VEGFR1 (3358
pixels/unit area) in normal lung, suggesting predominant
VEGFR2 signaling in both the normal lung as well as in the
injured (but recovering) lung. These observations are
consistent with an autocrine VEGF role in the lung on
alveolar epithelium in addition to its established paracrine
action on endothelium secreted from the epithelium. Such an
autocrine mechanism has been already described in epithelial
cells in the kidney but not yet in the lung [24].
Given the lack of previous studies and the difficulty in
obtaining human ARDS lung tissue, our study adds
significant and novel data to current knowledge. We have
looked at protein level changes with time in human ARDS
and quantified our immunostaining with biologically
plausible results.
We acknowledge the limitations of this study. Immuno-
histochemistry is primarily a localization technique, although
use of Histometrix in our study facilitated quantification.
Surgical lung biopsy from living ARDS patients would have
been preferred, but this is seldom performed due to the
241VEGF receptor expression in human ARDSrapidity of onset of ARDS, lack of thoracic surgeons on site,
and consent issues. We circumvented this problem using
necropsy lung tissue, although we cannot exclude selection
bias for a more severe spectrum of disease. Because
contemporaneous bronchoalveolar lavage fluid was unavail-
able from the ARDS subjects, we were unable to measure
contemporaneous levels of soluble VEGF receptors which
would be an important addition in future studies to
complement our work.
Existing human VEGF receptor regulation studies in
ARDS conflict. In agreement with our immunohistochemical
data, Lassus et al [25] demonstrated persistent expression of
VEGFR1 on vascular endothelial, bronchial epithelial, and
ATII cells in developing lungs with bronchopulmonary
dysplasia throughout the fetal and neonatal period. No
densitometry assessments were made. Perkins et al [23]
detected the presence of significant quantities of intrapul-
monary soluble VEGFR1 protein in early ARDS but did not
study VEGFR1, VEGFR2, or NRP-1. Conversely, Tsokos et
al [26] detected reduced VEGFR2 mRNA by real-time
polymerase chain reaction in human necropsy lung tissue
from septic patients. However, protein was not assessed, nor
was VEGFR1 or NRP-1; the patients did not strictly conform
to an ARDS phenotype and were assessed at varying time
points (4-28 days).
In animals, data also conflict. The strongest evidence
comes from intervention studies. Chronic VEGFR2 block-
ade in rats leads to alveolar apoptosis and emphysema [27],
suggesting a role in recovery from lung injury and a
possible survival function for VEGF via VEGFR2 on
alveolar epithelium. In contrast to our data, many studies
demonstrate a down-regulation in VEGF receptor expres-
sion after injury in the early stages. Ito et al [28] observed a
reduction in VEGFR1 and VEGFR2 mRNA expression 24
to 72 hours after LPS-induced murine lung injury in both
young and old mice. Time points were earlier and protein
was not measured. Mura et al [29] noted a reduction in lung
VEGFR1 (but not VEGFR2) expression in an ischemic/
reperfusion-induced murine mode of lung injury. This study
also confirmed VEGFR1 and VEGFR2 expression on both
sides of the alveolar-capillary membrane but with dis-
cordant features: notably, a reduction in alveolar epithelial,
alveolar macrophage, and interstitial VEGFR1 and a
redistribution of VEGFR2 positive cells into the inter-
stitium and ATII cells. Time points were again earlier (4
hours postinjury). Klekamp et al [18] noted a decrease in
VEGFR1 and VEGFR2 mRNA expression at 48 hours after
hyperoxic lung injury in rats. Protein was not assessed.
Tambunting et al [30] detected reduced mRNA expression
of VEGFR1, VEGFR2, and NRP-1, whereas Maniscalco
et al [31] observed reduced VEGFR1 mRNA expression
only (NRP-1 expression was not assessed in the latter)
both in baboon models of bronchopulmonary dysplasia.
Differences in methodology (ribonuclease protection assay
vs quantitative real-time polymerase chain reaction) might
account for these findings.Conversely, other animal studies suggest a pathological
role for VEGF in lung injury. Gurkan et al [32] noted an
increase in lung VEGFR2 protein after an acid-induced
murine lung injury model following high-tidal volume
ventilation, attenuated by a protective ventilatory strategy.
Time points were earlier (4 hours). Kazi et al [33] noted a
similar up-regulation of lung VEGFR2 mRNA and protein
expression for 24 hours in an ischemic model of murine lung
injury. Time points were earlier, and VEGFR1 and NRP-1
were not studied.
What are the implications of these findings? Existing data
conflict due to differing species, time points after injury,
phenotyping, methodologies, and the receptors studied. Our
data provide a potential mechanism for further functional
regulation of VEGF bioactivity with a reduced VEGFR2
signal in early injury and enhanced VEGFR2 signal in later
ARDS, providing further support for an autocrine protective
role for VEGF in the injured lung acting via VEGFR2.
Interventional studies suggest that these observations are
not epiphenomena.
Local VEGF delivery may be a potential new therapy for
acute lung injury, but further studies are needed to clarify the
mechanisms and functional consequences of these observa-
tions. These will include functional in vivo assessments of
VEGF receptor expression, receptor signaling studies, and
further VEGF receptor knockout studies in animal models of
lung injury.Acknowledgments
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